Best of SABCS® KYOTO 2021 Program Agenda

2021/1/9 (Sat)

Japan Standard Time Central European Time Central Standard Time(USA) Topic CME
Credits
1/9 9:00-9:20 1/9 1:00-1:20 1/8 18:00-18:20 Opening Ceremony
Opening Remarks (Masakazu Toi)
Opening messages from Eric P. Winer, Virginia Kaklamani, Ismail Jatoi , Reshma Jagsi		 0.25
1/9 9:20-10:25 1/9 1:20-2:25 1/8 18:20-19:25 Molecular signatures for prognosis, prediction and resistance : Virginia Kaklamani : Chair by Masakazu Toi
(presentation 20min. + short discussion 5 min.)
Adjuvant and neoadjuvant therapy updates : Masakazu Toi : Chair by Virginia Kaklamani
(presentation 20min. + short discussion 5 min.)		 1
Discussion & Break   Virginia Kaklamani, Masakazu Toi
1/9 10:25-10:50 1/9 2:25-2:50 1/8 19:25-19:50 Radiation Oncology : Reshma Jagsi : Chair by Chikako Yamauchi
(presentation 20min. + short discussion 5 min.)		 0.5
1/9 10:50-11:15 1/9 2:50-3:15 1/8 19:50-20:15 Advances in approaches to local-regional disease: Ismail Jatoi : Chair by Takashi Ishikawa
(presentation 20min. + short discussion 5 min.)		 0.5
1/9 11:15-11:40 1/9 3:15-3:40 1/8 20:15-20:40 Novel therapeutics in advanced disease: Shigehira Saji : Chair by Virginia Kaklamani
(presentation 20min. + short discussion 5 min.)		 0.5
1/9 11:40-12:20 1/9 3:40-4:20 1/8 20:40-21:20 General Discussion & Break : Virginia Kaklamani, Masakazu Toi, Reshma Jagsi, Chikako Yamauchi, Ismail Jatoi, Takashi Ishikawa, Shigehira Saji
1/9 12:20-13:20 1/9 4:20-5:20 1/8 21:20-22:20 Luncheon seminar  Title: Treatment for HER2-positive MBC
MasahiroTakada chair by Shigehira Saji
Co-organized with Daiichi-Sankyo Co.,Ltd
1/9 13:20-13:30 1/9 5:20-5:30 1/8 22:20-22:30 Break
1/9 13:30-14:00 1/9 5:30-6:00 1/8 22:30-23:00 Case discussion: Chair: Takahiro Nakayama
Panel: Kumiko Kida, Masaya Hattori, Toshiyuki Ishiba, Yoshiaki Matsumoto		 0.5
1/9 14:00-14:25 1/9 6:00-6:25 1/8 23:00-23:25 Adjuvant Treatment for DCIS
Yasuaki Sagara chair by Wakako Tsuji
(presentation 20min. + short discussion 5 min.)		 0.5
1/9 14:25-14:35 1/9 6:25-6:35 1/8 23:25-23:35 Discussion & Break 0.5
1/9 14:35-15:00 1/9 6:35-7:00 1/8 23:35-24:00 Germline tests and variants and high-risk management
Hideko Yamauchi chair by Nobuhiko Shinkura
(presentation 20min. + short discussion 5 min.)
1/9 15:00-16:00 1/9 7:00-8:00 1/9 0:00-1:00 Evening seminar  Chair by Hideko Yamauchi
Hereditary breast cancer in Japan: Nobuko Kawaguchi
Challenges to overcome PARPi resistance: Tomohiko Ohta
Co-organized with AstraZeneca
1/9 16:00-16:20 1/9 8:00-8:20 1/91:00- 1:20 Discussion & Break  Hideko Yamauchi, Nobuko Kawaguchi, Tomohiko Ohta, Nobuhiko Shinkura 0.75
1/9 16:20-17:05 1/9 8:20-9:05 1/9 1:20-2:05 Debate session (Chemotherapy indication for intermediate risk patients)
by Kazuhiko Yamagami / Yoichi Naito
Panel Discussion, Audience Q and A (Zoom chat system)
Pro/ Con:
A:Yuichiro Kikawa / Takayuki Iwamoto
B:Yukinori Ozaki / Toshimi Takano

2021/1/10 (Sun)

Japan Standard Time Central European Time Central Standard Time(USA) Topic CME Credits
1/10 10:20-11:20 1/10 2:20-3:20 1/9 19:20-20:20 Morning seminar  Title: The Imaging of Tumor Microenvironment
Dai Fukumura  Chair by Kosuke Kawaguchi
Co-organized with Eisai Co.,Ltd
1/10 11:20-12:50 1/10 3:20-4:50 1/9 20:20-21:50 Techniques to Improve Abstract Writing for Acceptance And how to submit an abstract to the SABCS® by Prof. Jatoi & Prof. Toi (A paid course)
Topics
 1) Writing a scientific manuscript
 2) Presentation of scientific papers
 3) Prof. Toi and Dr. Jatoi's lecture		 2
1/10 12:50-13:00 1/10 4:50-5:00 1/9 21:50-22:00 Break
1/10 13:00-14:00 1/10 5:00-6:00 1/9 22:00-23:00 Luncheon Seminar Title: The impact of CDK4 & 6 inhibitor on ER-positive advanced breast cancer - Evidence and Practice -
Jun-ichiro Watanabe chair by Yasuo Miyoshi
Co-organized with Eli Lilly Japan K. K.
1/10 14:00-14:15 1/10 6:00-6:15 1/9 23:00-23:15 Break
1/10 14:15-15:25 1/10 6:15-7:25 1/9 23:15-1/10 0:25 Guideline Session; what would be changed and what needs to be discussed, particularly after SABCS 2020
Chair by Hiroji Iwata
・Japan：Shigehira Saji
・India：Dinesh C. Doval
・Korea：Yeon Hee Park
1/10 15:25-15:40 1/10 7:25-7:40 1/10 0:25-0:40 Break
1/10 15:40-16:05 1/10 7:40-8:05 1/10 0:40-1:05 New directions in translational research and resistance mechanisms
Takayuki Ueno  Chair by Louis Chow
(presentation 20min. + short discussion 5 min.)		 0.5
1/10 16:05-16:30 1/10 8:05-8:30 1/10 1:05-1:30 Immunotherapy and biomarkers of benefit
Tomoharu Sugie Chair by Junji Tsurutani
(presentation 20min. + short discussion 5 min.)		 0.5
1/10 16:30-17:00 1/10 8:30-9:00 1/10 1:30-2:00 Discussion & Break  Takayuki Ueno, Louis Chow, Tomoharu Sugie, Junji Tsurutani
1/10 17:00-18:10 1/10 9:00-10:10 1/10 2:00-3:10 Debate session (Metastatic breast cancer with triple negative subtype)
by Akira Yamauchi and Sachiko Takahara

Literature review (5min) Eiji Suzuki

<1st case> Metaplastic breast cancer with triple negative subtype Case 1
Case presentation : Akira Yamauchi

Plan A team: Yukiko Fukui / Nobuko Kawaguchi 5min
Plan B team: Uhi Toh /Eriko Tokunaga 5min

Discussion (5min), and Voting of the audience

<2nd case> Metaplastic breast cancer with triple negative subtype Case 2
Case presentation : Sachiko Takahara

Plan A team: Fumikata Hara 5min
Plan B team: Tetsuhiro Yoshinami 5min
Discussion 5min and Voting of the audience		 1.25
1/10 18:10-18:15 1/10 10:10-10:15 1/10 3:10-3:15 Closing remarks by Nobuhiko Shinkura
1/10 18:15-19:15 +α 1/10 10:15-11:15 +α 1/10 3:15-4:15 +α KBCCC session (Language : Japanese )
日本と世界における法規制の違い、日本（アジア）からできる action のために
下井辰徳、 仲野兼司、深田一平、尾崎由記範、他希望者　Chair by 下村昭彦

座長：下村昭彦
1. 現在の乳がんにおけるドラッグラグについて (下村昭彦)
2. 規制当局の基本的な考え方〜ドラッグラグはなぜ起きる? 規制当局はどう対応している? ジャパンパッシングを含めて〜 (深田一平)
3. 新薬を早期に提供するためのこころみ～先駆け申請制度による承認を経験して～(仲野兼司)
4. 適応外使用〜当該疾患には承認されていないが、薬そのものは手の内にある場合の対応〜 (下井辰徳)
5. 医師主導治験〜企業が開発しない領域を医師主導で切り開く〜 (尾崎由記範)
6. 総合ディスカッション